A groundbreaking innovation from a collaborative team at ETH Zurich and Karolinska Institutet is poised to revolutionize early-stage drug discovery…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry finds itself at a critical juncture, grappling with escalating costs, protracted timelines, and persistently high failure rates…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, public discourse surrounding drug pricing frequently fixates on the list price. Annual…
Read More
Canadian Researchers Identify Existing HIV Drug as Potential Breakthrough Treatment for Aggressive Glioblastoma Brain Cancer
In a significant advancement for neuro-oncology, a collaborative team of scientists in Canada has uncovered a novel mechanism to impede…
Read More
Apotex Acquires Cumberland Pharmaceuticals’ Branded Drug Portfolio for $100 Million, Ushering in New Era for Both Companies
Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
AI Governance and Trust: The Bedrock for Scaling Innovation in Drug Development
The accelerating adoption of artificial intelligence (AI) within the pharmaceutical industry is not merely a technological advancement; it is a…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
Unlocking the Genetic Keys to GLP-1 Drug Efficacy and Side Effects
A groundbreaking study involving over 23andMe customers has identified genetic variations in two key genes that significantly influence both the…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
US President Signs Executive Order to Expedite Psychedelic Drug Review and Bolster Research
In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
